Exciting Approval in Europe for HER2-Positive Breast Cancer

EP. 1: European Commission Approval of Tucatinib in HER2+ BC

April 7th 2021

Volkmar Mueller, MD, reviews recent data from the HER2CLIMB trial and discusses the recent regulatory approval in Europe for patients with HER2+ breast cancer.

EP. 2: Favorable Safety Profile of Tucatinib for Metastatic HER2+ BC

April 7th 2021

Experts in breast oncology review the favorable safety profile of tucatinib for patients with metastatic HER2+ breast cancer.

EP. 3: Real-World Experience With Tucatinib in Germany and France

April 7th 2021

An examination of the real-world data supporting the use of tucatinib for patients with metastatic HER2+ breast cancer in Europe.

EP. 4: Clinical Implications of Tucatinib Approval in Europe 

April 14th 2021

Experts discuss the clinical implications of the approval of tucatinib in Europe, specifically for patients with active brain metastases.

EP. 5: Approaches to Sequencing for Metastatic HER2+ BC

April 14th 2021

Volkmar Mueller, MD, shares insight on the potential sequencing of available therapeutics for patients with metastatic HER2+ breast cancer.

EP. 6: Unanswered Questions in HER2+ Breast Cancer

April 14th 2021

Considerations on the evolving landscape and ongoing unmet needs for patients with HER2+ breast cancer.